Logo.png
IMUNON Reports Compliance with Nasdaq Listing Requirements
April 11, 2024 08:00 ET | Imunon, Inc.
LAWRENCEVILLE, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated...
Logo edited.jpg
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
March 13, 2024 06:00 ET | Greenwich LifeSciences, Inc.
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Logo.png
IMUNON Announces Leadership Change
March 12, 2024 17:00 ET | Imunon, Inc.
Executive Chairman to lead day-to-day operations, active search underway for CEO successor.Timing of upcoming milestones for key programs remains unchanged.  LAWRENCEVILLE, N.J., March 12, 2024 ...
Logo.png
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
February 27, 2024 08:30 ET | Imunon, Inc.
Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...
Logo.png
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
February 22, 2024 08:00 ET | Imunon, Inc.
Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
logo.jpg
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
February 21, 2024 08:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Logo.png
Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN
February 14, 2024 15:55 ET | Tevogen Bio Holdings Inc.
Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large...
Logo edited.jpg
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
February 14, 2024 06:00 ET | Greenwich LifeSciences, Inc.
STAFFORD, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an...
Logo.jpg
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
January 29, 2024 08:30 ET | Lixte Biotechnology Holdings, Inc.
PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a Phase...
logo.jpg
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
January 18, 2024 07:45 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...